Why the study?
Although GDMT is recommended prior to M-TEER, not all patients tolerate it, leaving the association of GDMT prescription with survival unclear in HFrEF patients undergoing M-TEER for secondary mitral regurgitation.
Does triple GDMT prescription improve 2-year survival in HFrEF patients undergoing M-TEER for secondary mitral regurgitation?
Does triple GDMT prescription improve 2-year survival in HFrEF patients undergoing M-TEER for secondary mitral regurgitation?
Answers are grounded in this paper and cite their sources.
Triple GDMT prescription at the time of M-TEER is associated with improved 2-year survival in HFrEF patients with secondary mitral regurgitation, including those with major comorbidities or suboptimal procedural results.
AIMS: Guideline-directed medical therapy (GDMT), based on the combination of beta-blockers (BB), renin-angiotensin system inhibitors (RASI), and mineralocorticoid receptor antagonists (MRA), is known to have a major impact on the outcome of patients with heart failure with reduced ejection fraction (HFrEF). Although GDMT is recommended prior to mitral valve transcatheter edge-to-edge repair (M-TEER), not all patients tolerate it. We studied the association of GDMT prescription with survival in HFrEF patients undergoing M-TEER for secondary mitral regurgitation (SMR). METHODS AND RESULTS: EuroSMR, a European multicentre registry, included SMR patients with left ventricular ejection fraction <50%. The outcome was 2-year all-cause mortality. Of 1344 patients, BB, RASI, and MRA were prescribed in 1169 (87%), 1012 (75%), and 765 (57%) patients at the time of M-TEER, respectively. Triple GDMT prescription was associated with a lower 2-year all-cause mortality compared to non-triple GDMT (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.60-0.91). The association persisted in patients with glomerular filtration rate <30 ml/min, ischaemic aetiology, or right ventricular dysfunction. Further, a positive impact of triple GDMT prescription on survival was observed in patients with residual mitral regurgitation of ≥2+ (HR 0.62; 95% CI 0.44-0.86), but not in patients with residual mitral regurgitation of ≤1+ (HR 0.83; 95% CI 0.64-1.08). CONCLUSION: Triple GDMT prescription is associated with higher 2-year survival after M-TEER in HFrEF patients with SMR. This association was consistent also in patients with major comorbidities or non-optimal results after M-TEER.
No takes yet. Share an insight, caveat, or question.
Higuchi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: